hmr 1766 has been researched along with Disease Models, Animal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Bauersachs, J; Fraccarollo, D; Galuppo, P; Motschenbacher, S; Ruetten, H; Schäfer, A | 1 |
| Amann, K; Benz, K; Linz, W; Orth, SR; Rütten, H; Schindler, U; Simonaviciene, A | 1 |
3 other study(ies) available for hmr 1766 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiotonic Agents; Cell Communication; Cells, Cultured; Disease Models, Animal; Drug Therapy, Combination; Enzyme Activation; Enzyme Activators; Extracellular Matrix; Fibrosis; Guanylate Cyclase; Heart Failure; Hemodynamics; Humans; Male; Mice; Mitochondria, Heart; Myocardial Contraction; Myocardial Infarction; Myocytes, Cardiac; Myofibroblasts; Nitric Oxide; Nitric Oxide Synthase Type III; ortho-Aminobenzoates; Oxidative Stress; Ramipril; Rats, Wistar; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Superoxides; Time Factors; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Blood pressure-independent effect of long-term treatment with the soluble heme-independent guanylyl cyclase activator HMR1766 on progression in a model of noninflammatory chronic renal damage.
Topics: Animals; Blood Pressure; Disease Models, Animal; Disease Progression; Guanylate Cyclase; Heme; Kidney Failure, Chronic; Male; ortho-Aminobenzoates; Rats; Rats, Sprague-Dawley; Receptors, Cytoplasmic and Nuclear; Soluble Guanylyl Cyclase; Sulfonamides; Time | 2007 |